Paul Mahon A.'s most recent trade in United Therapeutics Corp was a trade of 11,000 Common Stock done at an average price of $135.4 . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. | 26 Jun 2025 | 11,000 | 47,781 (0%) | 0% | 135.4 | 1,489,620 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2025 | 11,000 | 121,000 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 285.01 per share. | 26 Jun 2025 | 3,940 | 41,304 (0%) | 0% | 285.0 | 1,122,930 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 284.10 per share. | 26 Jun 2025 | 2,537 | 45,244 (0%) | 0% | 284.1 | 720,769 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 287.21 per share. | 26 Jun 2025 | 2,334 | 38,031 (0%) | 0% | 287.2 | 670,354 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 287.92 per share. | 26 Jun 2025 | 1,150 | 36,881 (0%) | 0% | 287.9 | 331,110 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 286.13 per share. | 26 Jun 2025 | 939 | 40,365 (0%) | 0% | 286.1 | 268,676 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 288.80 per share. | 26 Jun 2025 | 100 | 36,781 (0%) | 0% | 288.8 | 28,880 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 11,000 | 132,000 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. | 12 Jun 2025 | 11,000 | 47,781 (0%) | 0% | 135.4 | 1,489,620 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 281.56 per share. | 12 Jun 2025 | 4,557 | 36,981 (0%) | 0% | 281.6 | 1,283,063 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 278.41 per share. | 12 Jun 2025 | 1,837 | 44,338 (0%) | 0% | 278.4 | 511,441 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 279.51 per share. | 12 Jun 2025 | 1,425 | 42,913 (0%) | 0% | 279.5 | 398,303 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 280.70 per share. | 12 Jun 2025 | 1,375 | 41,538 (0%) | 0% | 280.7 | 385,957 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 276.95 per share. | 12 Jun 2025 | 1,100 | 46,175 (0%) | 0% | 277.0 | 304,648 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 275.98 per share. | 12 Jun 2025 | 506 | 47,275 (0%) | 0% | 276.0 | 139,647 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 282.27 per share. | 12 Jun 2025 | 200 | 36,781 (0%) | 0% | 282.3 | 56,454 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. | 29 May 2025 | 7,000 | 43,781 (0%) | 0% | 135.4 | 947,940 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 7,000 | 143,000 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 316.57 per share. | 29 May 2025 | 4,573 | 37,305 (0%) | 0% | 316.6 | 1,447,661 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 4,000 | 0 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 315.77 per share. | 29 May 2025 | 4,000 | 43,781 (0%) | 0% | 315.8 | 1,263,080 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 29 May 2025 | 4,000 | 47,781 (0%) | 0% | 117.8 | 471,040 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 315.53 per share. | 29 May 2025 | 1,703 | 41,878 (0%) | 0% | 315.5 | 537,353 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 317.19 per share. | 29 May 2025 | 524 | 36,781 (0%) | 0% | 317.2 | 166,209 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 313.46 per share. | 29 May 2025 | 101 | 43,581 (0%) | 0% | 313.5 | 31,659 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 311.14 per share. | 29 May 2025 | 99 | 43,682 (0%) | 0% | 311.1 | 30,803 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 11,000 | 4,000 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 15 May 2025 | 11,000 | 47,781 (0%) | 0% | 117.8 | 1,295,360 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 295.10 per share. | 15 May 2025 | 5,004 | 39,534 (0%) | 0% | 295.1 | 1,476,680 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 293.31 per share. | 15 May 2025 | 2,139 | 45,642 (0%) | 0% | 293.3 | 627,399 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 296.40 per share. | 15 May 2025 | 1,744 | 37,790 (0%) | 0% | 296.4 | 516,930 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 293.95 per share. | 15 May 2025 | 1,104 | 44,538 (0%) | 0% | 294.0 | 324,526 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 297.33 per share. | 15 May 2025 | 800 | 36,990 (0%) | 0% | 297.3 | 237,866 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 300.24 per share. | 15 May 2025 | 203 | 36,783 (0%) | 0% | 300.2 | 60,948 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 299.00 per share. | 15 May 2025 | 4 | 36,986 (0%) | 0% | 299 | 1,196 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 302.00 per share. | 15 May 2025 | 2 | 36,781 (0%) | 0% | 302 | 604 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 01 May 2025 | 11,000 | 47,781 (0%) | 0% | 117.8 | 1,295,360 | Common Stock |
| United Therapeutics Corp | A. Mahon Paul | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 11,000 | 15,000 | - | - | Stock Option | |
| United Therapeutics Corp | A. Mahon Paul | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 302.71 per share. | 01 May 2025 | 3,859 | 36,901 (0%) | 0% | 302.7 | 1,168,141 | Common Stock |
| United Therapeutics Corp | Paul Mahon A. | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 301.81 per share. | 01 May 2025 | 3,392 | 40,760 (0%) | 0% | 301.8 | 1,023,747 | Common Stock |
| United Therapeutics Corp | A. Mahon Paul | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 300.63 per share. | 01 May 2025 | 1,320 | 44,152 (0%) | 0% | 300.6 | 396,830 | Common Stock |
| United Therapeutics Corp | Mahon A. Paul | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 295.12 per share. | 01 May 2025 | 870 | 46,911 (0%) | 0% | 295.1 | 256,755 | Common Stock |
| United Therapeutics Corp | Mahon Paul A. | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 299.05 per share. | 01 May 2025 | 500 | 45,472 (0%) | 0% | 299.1 | 149,525 | Common Stock |
| United Therapeutics Corp | A. Mahon Paul | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 296.00 per share. | 01 May 2025 | 400 | 46,511 (0%) | 0% | 296.0 | 118,399 | Common Stock |
| United Therapeutics Corp | Mahon Paul A. | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 298.05 per share. | 01 May 2025 | 300 | 45,972 (0%) | 0% | 298.1 | 89,416 | Common Stock |
| United Therapeutics Corp | A. Mahon Paul | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 297.00 per share. | 01 May 2025 | 239 | 46,272 (0%) | 0% | 297 | 70,983 | Common Stock |
| United Therapeutics Corp | A. Paul Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 303.38 per share. | 01 May 2025 | 120 | 36,781 (0%) | 0% | 303.4 | 36,406 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 17 Apr 2025 | 11,000 | 47,781 (0%) | 0% | 117.8 | 1,295,360 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2025 | 11,000 | 26,000 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 283.83 per share. | 17 Apr 2025 | 5,488 | 39,877 (0%) | 0% | 283.8 | 1,557,635 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 284.69 per share. | 17 Apr 2025 | 3,096 | 36,781 (0%) | 0% | 284.7 | 881,396 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 282.92 per share. | 17 Apr 2025 | 2,016 | 45,365 (0%) | 0% | 282.9 | 570,371 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 280.35 per share. | 17 Apr 2025 | 400 | 47,381 (0%) | 0% | 280.4 | 112,141 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2025 | 11,000 | 37,000 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 03 Apr 2025 | 11,000 | 47,781 (0%) | 0% | 117.8 | 1,295,360 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 307.12 per share. | 03 Apr 2025 | 3,787 | 38,282 (0%) | 0% | 307.1 | 1,163,054 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 305.08 per share. | 03 Apr 2025 | 3,094 | 44,287 (0%) | 0% | 305.1 | 943,928 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 306.08 per share. | 03 Apr 2025 | 2,218 | 42,069 (0%) | 0% | 306.1 | 678,889 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 308.08 per share. | 03 Apr 2025 | 1,501 | 36,781 (0%) | 0% | 308.1 | 462,430 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 300.42 per share. | 03 Apr 2025 | 200 | 47,381 (0%) | 0% | 300.4 | 60,083 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 298.00 per share. | 03 Apr 2025 | 200 | 47,581 (0%) | 0% | 298 | 59,600 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 6,550 | 0 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 06 Mar 2025 | 6,550 | 43,331 (0%) | 0% | 163.3 | 1,069,615 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 307.68 per share. | 06 Mar 2025 | 6,550 | 36,781 (0%) | 0% | 307.7 | 2,015,304 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 20 Feb 2025 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2025 | 7,700 | 6,550 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 367.36 per share. | 20 Feb 2025 | 7,700 | 36,710 (0%) | 0% | 367.4 | 2,828,672 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 7,700 | 14,250 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 353.75 per share. | 06 Feb 2025 | 7,700 | 36,710 (0%) | 0% | 353.8 | 2,723,875 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 06 Feb 2025 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 16 Jan 2025 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2025 | 7,700 | 21,950 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 366.39 per share. | 16 Jan 2025 | 7,700 | 36,710 (0%) | 0% | 366.4 | 2,821,203 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 02 Jan 2025 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 360.22 per share. | 02 Jan 2025 | 7,700 | 36,710 (0%) | 0% | 360.2 | 2,773,694 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 7,700 | 29,650 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 360.16 per share. | 19 Dec 2024 | 7,700 | 36,710 (0%) | 0% | 360.2 | 2,773,232 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 7,700 | 37,350 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 19 Dec 2024 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 374.37 per share. | 05 Dec 2024 | 7,700 | 36,710 (0%) | 0% | 374.4 | 2,882,649 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2024 | 7,700 | 45,050 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 05 Dec 2024 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2024 | 7,700 | 52,750 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 21 Nov 2024 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 367.36 per share. | 21 Nov 2024 | 7,700 | 36,710 (0%) | 0% | 367.4 | 2,828,672 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 07 Nov 2024 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 7,700 | 60,450 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 402.57 per share. | 07 Nov 2024 | 7,700 | 36,710 (0%) | 0% | 402.6 | 3,099,789 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 03 Oct 2024 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 350.07 per share. | 03 Oct 2024 | 7,700 | 36,710 (0%) | 0% | 350.1 | 2,695,539 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 03 Oct 2024 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 372.81 per share. | 03 Oct 2024 | 7,700 | 36,710 (0%) | 0% | 372.8 | 2,870,637 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 7,700 | 75,850 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 7,700 | 68,150 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 7,700 | 83,550 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 351.33 per share. | 19 Sep 2024 | 7,700 | 36,710 (0%) | 0% | 351.3 | 2,705,241 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 19 Sep 2024 | 7,700 | 44,410 (0%) | 0% | 163.3 | 1,257,410 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 91,250 | - | - | Share Tracking Award | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale or transfer of securities back to the company at price $ 308.98 per share. | 20 Jun 2024 | 25,000 | 36,710 (0%) | 0% | 309.0 | 7,724,500 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 163.30 per share. | 20 Jun 2024 | 25,000 | 61,710 (0%) | 0% | 163.3 | 4,082,500 | Common Stock |